ArticleApplied microbiology and biotechnology2026
The visualizable and marker-free gene editing platform mediated by CRISPR/Cas9 in Coleophoma empetri.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Micafungin, an echinocandin antifungal agent, has been extensively utilized for the treatment of invasive fungal infections. It is semi-synthesized from the lipohexapeptide FR901379, a natural product from the filamentous fungus Coleophoma empetri. The genetic manipulation of C. empetri has been significantly hindered by the scarcity of both effective neutral sites and selectable markers, which has impeded the systematic metabolic engineering of the industrial strain. Here, a visualizable and marker-free gene editing platform was developed in the industrial strain C. empetri MEFC09. Firstly, the biosynthesis gene cluster of melanin in C. empetri MEFC09 was characterized by gene knockoutin vivo, which comprises a core polyketide synthase gene cemelA and a transcriptional regulator cemelR. Based on this, two neutral sites were designed at the genomic loci of cemelA and cemelR, both demonstrating high-intensity expression of the luciferase reporter. Furthermore, a CRISPR/Cas9-mediated marker-free gene editing platform was developed. When the protoplast concentration was adjusted to 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.